表紙
市場調査レポート

癌バイオマーカーの世界市場 〜2020年:腫瘍別 (乳癌、肺癌、前立腺癌)・種類別 (タンパク質/遺伝子バイオマーカー)・プロファイリング技術別 (プロテオミクス、ゲノミクス、画像診断、免疫検定)・用途別 (診断、創薬、予後)・地域別の将来予測

Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography: Global Forecast to 2020

発行 MarketsandMarkets 商品コード 118897
出版日 ページ情報 英文 259 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
癌バイオマーカーの世界市場 〜2020年:腫瘍別 (乳癌、肺癌、前立腺癌)・種類別 (タンパク質/遺伝子バイオマーカー)・プロファイリング技術別 (プロテオミクス、ゲノミクス、画像診断、免疫検定)・用途別 (診断、創薬、予後)・地域別の将来予測 Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography: Global Forecast to 2020
出版日: 2015年08月28日 ページ情報: 英文 259 Pages
概要

世界の癌バイオマーカー市場の成長要因として、世界各国での医療費支出額の増加や、研究開発 (R&D) 支出額の拡大、診断時におけるバイオマーカーの有用性の改善、CRO (開発受託機関) の増加、途上国での低コストでの治験などが挙げられます。

当レポートでは、世界の癌 (腫瘍) バイオマーカーの市場について分析し、技術的概要や市場の基本的構造・最新動向、主な市場促進・阻害要因、市場規模の動向見通し (今後6年間分)、腫瘍別・種類別・技術別・用途別・地域別の詳細動向、市場競争の状態、今後の技術開発・市場発展の方向性、主要企業のプロファイルなどを調査・考察しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場の内訳
  • 市場のダイナミクス
    • 促進因子
      • 技術進歩
      • 癌の発症件数の増加
      • 正確性・診断速度の改善
      • 創薬・開発段階での癌バイオマーカーの利用増加
      • 癌バイオマーカーに関する研究の拡大
      • FDA (米国食品医薬品局) によるバイオマーカー開発への支援
    • 阻害因子
      • 不適切な規制・医療費償還制度
      • 資本投資額の大きさと収益・コスト比率の低さ
      • サンプル収集・貯蔵に関する技術的課題
    • 市場機会
      • 個別化医療
      • コンパニオン診断
      • 新興国市場
    • 課題
      • バイオマーカー関連検査の臨床的妥当性・有用性の検証過程が、その受容度の低さにつながる

第6章 産業動向

  • イントロダクション
  • 産業動向
  • ポーターのファイブフォース分析

第7章 世界の癌バイオマーカー市場:癌の種類別

  • イントロダクション
  • 肺癌
  • 大腸癌
  • 前立腺癌
  • 子宮頚部癌
  • その他の癌

第8章 癌バイオマーカー市場:種類別

  • イントロダクション
  • タンパク質バイオマーカー
  • ジェネティックバイオマーカー
  • その他の癌バイオマーカー

第9章 癌バイオマーカー市場:プロファイリング技術別

  • イントロダクション
  • オミクス技術
    • プロテオミクス
    • ゲノミクス
      • 次世代型シーケンシング (NGS)
      • マイクロアレイ
      • ポリマー連鎖反応 (PCR)
    • その他
  • 画像技術
    • 超音波
    • CT (コンピューター断層撮影法)
    • MRI (核磁気共鳴画像診断)
    • 陽電子放出型コンピューター断層撮影法 (PET)
    • マンモグラフィー
  • 免疫検定
    • 免疫組織化学 (IHC)
    • フローサイトメトリー
    • 酵素免疫測定法 (ELISA法)
  • 細胞遺伝学
    • in situ ハイブリダイゼーション (ISH)
    • その他
  • バイオインフォマティクス (生物情報学)

第10章 癌バイオマーカー市場:用途別

  • イントロダクション
  • 診断
  • 創薬・医薬品開発
  • 予後徴候
  • リスク評価
  • その他の用途

第11章 癌バイオマーカー市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 他のアジア太平洋地域諸国
  • 他の国々 (ROW)
    • ラテンアメリカ
    • 中東・アフリカ

第12章 競争環境

  • 概要
  • 市場シェア分析
  • 競争状況と動向
    • 新製品の発売
    • 契約
    • 企業買収
    • 事業協力
    • その他

第13章 企業プロファイル (概要、財務状況、製品・サービス、戦略、近年の動向)

  • イントロダクション
  • ABBOTT LABORATORIES
  • AFFYMETRIX, INC.
  • ILLUMINA, INC.
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS LTD.
  • AGILENT TECHNOLOGIES, INC.
  • QUEST DIAGNOSTICS INC.
  • MERCK & CO. INC.
  • HOLOGIC, INC.
  • BECTON, DICKINSON AND COMPANY

第14章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3693

In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation:Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
  • Competitive Assessment:In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
  • Market Development:Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
  • Market Diversification:Exhaustive information about new products, recent developments, and investments in the biomarkers market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY AND PRICING
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. KEY DATA FROM SECONDARY SOURCES
  • 2.6. KEY DATA FROM PRIMARY SOURCES
    • 2.6.1. KEY INDUSTRY INSIGHTS
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. GROWTH POTENTIAL OF THE GLOBAL CANCER BIOMARKERS MARKET
  • 4.2. ASIA-PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY (2014)
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE GLOBAL CANCER BIOMARKERS MARKET
  • 4.4. GLOBAL CANCER BIOMARKERS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY TYPE
    • 5.2.2. BY TUMOR TYPE
    • 5.2.3. BY PROFILING TECHNOLOGIES
    • 5.2.4. BY APPLICATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Technological advancements
      • 5.3.1.2. Rising Incidence of cancer
      • 5.3.1.3. Enhanced accuracy and speed of diagnosis
      • 5.3.1.4. Increasing use of cancer biomarkers in drug discovery and development
      • 5.3.1.5. Increasing research on cancer biomarkers
      • 5.3.1.6. FDA support for biomarker development
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Poorly suited regulatory and reimbursement systems
      • 5.3.2.2. High capital investment and low benefit-cost ratio
      • 5.3.2.3. Technical issues related to sample collection and storage
    • 5.3.3. OPPORTUNITITES
      • 5.3.3.1. Personalized medicine
      • 5.3.3.2. Companion diagnostics
      • 5.3.3.3. Emerging economies
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Proving clinical validity and utility of biomarker-based tests leading to their insufficient acceptance

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. INDUSTRY TRENDS
  • 6.3. PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1. THREAT OF NEW ENTRANTS
    • 6.3.2. THREAT OF SUBSTITUTES
    • 6.3.3. BARGAINING POWER OF SUPPLIERS
    • 6.3.4. BARGAINING POWER OF BUYERS
    • 6.3.5. INTENSITY OF COMPETITIVE RIVALRY

7. GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE

  • 7.1. INTRODUCTION
  • 7.2. LUNG CANCER
  • 7.3. COLORECTAL CANCER
  • 7.4. PROSTATE CANCER
  • 7.5. CERVICAL CANCER
  • 7.6. OTHER CANCERS

8. CANCER BIOMARKERS MARKET, BY TYPE

  • 8.1. INTRODUCTION
  • 8.2. PROTEIN BIOMARKERS
  • 8.3. GENETIC BIOMARKERS
  • 8.4. OTHER CANCER BIOMARKERS

9. CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

  • 9.1. INTRODUCTION
  • 9.2. OMICS TECHNOLOGIES
    • 9.2.1. PROTEOMICS
    • 9.2.2. GENOMICS
      • 9.2.2.1. Next Generation Sequencing (NGS)
      • 9.2.2.2. Microarrays
      • 9.2.2.3. Polymer Chain Reaction (PCR)
    • 9.2.3. OTHER OMICS TECHNOLOGIES
  • 9.3. IMAGING TECHNOLOGIES
    • 9.3.1. ULTRASOUND
    • 9.3.2. COMPUTED TOMOGRAPHY (CT)
    • 9.3.3. MAGNETIC RESONANCE IMAGING (MRI)
    • 9.3.4. POSITRON EMISSION TOMOGRAPHY (PET)
    • 9.3.5. MAMMOGRAPHY
  • 9.4. IMMUNOASSAYS
    • 9.4.1. IMMUNOHISTOCHEMISTRY (IHC)
    • 9.4.2. FLOW CYTOMETRY
    • 9.4.3. ELISA
  • 9.5. CYTOGENETICS
    • 9.5.1. IN SITU HYBRIDIZATION (ISH)
    • 9.5.2. OTHERS
  • 9.6. BIOINFORMATICS

10. CANCER BIOMARKERS MARKET, BY APPLICATION

  • 10.1. INTRODUCTION
  • 10.2. DIAGNOSTICS
  • 10.3. DRUG DISCOVERY AND DEVELOPMENT
  • 10.4. PROGNOSTICS
  • 10.5. RISK ASSESSMENT
  • 10.6. OTHER APPLICATIONS

11. CANCER BIOMARKERS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. U.K.
    • 11.3.3. FRANCE
    • 11.3.4. ITALY
    • 11.3.5. SPAIN
    • 11.3.6. REST OF EUROPE (ROE)
  • 11.4. ASIA-PACIFIC
    • 11.4.1. JAPAN
    • 11.4.2. CHINA
    • 11.4.3. INDIA
    • 11.4.4. REST OF APAC
  • 11.5. REST OF THE WORLD (ROW)
    • 11.5.1. LATIN AMERICA
    • 11.5.2. MIDDLE EAST AND AFRICA

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATIONS AND TRENDS.
    • 12.3.1. NEW PRODUCT LAUNCHES
    • 12.3.2. AGREEMENTS
    • 12.3.3. ACQUISITIONS
    • 12.3.4. COLLABORATIONS
    • 12.3.5. OTHERS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. ABBOTT LABORATORIES
  • 13.3. AFFYMETRIX, INC.
  • 13.4. ILLUMINA, INC.
  • 13.5. QIAGEN N.V.
  • 13.6. ROCHE DIAGNOSTICS LTD.
  • 13.7. AGILENT TECHNOLOGIES, INC.
  • 13.8. QUEST DIAGNOSTICS INC.
  • 13.9. MERCK & CO. INC.
  • 13.10. HOLOGIC, INC.
  • 13.11. BECTON, DICKINSON AND COMPANY

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. RECENT DEVELOPMENTS, BY MARKET PLAYER, 2011-2015
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. INTRODUCTION RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF CANCER ARE DRIVING THE GROWTH OF THE CANCER BIOMARKERS MARKET
  • TABLE 2: POORLY SUITED REGULATORY AND REIMBURSEMENT SYSTEMS OF BIOMARKER TESTS ARE RESTRAINING THE GROWTH OF CANCER BIOMARKERS MARKET
  • TABLE 3: PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS PRESENT AN ARRAY OPPORTUNITITES FOR THE GROWTH OF CANCER BIOMARKERS MARKET.
  • TABLE 4: INSUFFICIENT ACCEPTANCE, PROVING CLINICAL VALIDITY AND UTILITY OF BIOMARKER-BASED TESTS ARE A MAJOR CHALLENGE IN THE CANCER BIOMARKERS MARKET
  • TABLE 5: GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 6: GLOBAL BREAST CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 7: GLOBAL LUNG CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 8: GLOBAL COLORECTAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 9: GLOBAL PROSTATE CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 10: GLOBAL CERVICAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 11: GLOBAL OTHER CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 12: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 13: PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: GENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: OTHER CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 16: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 17: GLOBAL OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 18: GLOBAL OMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 19: GLOBAL PROTEOMICS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 20: GLOBAL GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 21: GLOBAL GENOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY (USD MILLION)
  • TABLE 22: GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 24: GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 25: GLOBAL OTHER OMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 26: GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 27: GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 32: GLOBAL MAMMOGRAPHY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: GLOBAL IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 34: GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 35: GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 36: GLOBAL FLOW CYTOMETRY MARKET, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 37: GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 38: GLOBAL CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 39: GLOBAL CYTOGENETICS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 40: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 41: GLOBAL OTHER CYTOGENETICS TESTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 42: GLOBAL BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2013-2020, USD MILLION
  • TABLE 43: GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 44: GLOBAL CANCER BIOMARKERS MARKET SIZE FOR DIAGNOSTICS APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
  • TABLE 45: GLOBAL CANCER BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
  • TABLE 46: GLOBAL CANCER BIOMARKERS MARKET SIZE FOR PROGNOSTICS APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
  • TABLE 47: GLOBAL CANCER BIOMARKERS MARKET SIZE FOR RISK ASSESSMENT APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
  • TABLE 48: GLOBAL CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2013-2020 (USD MILLION)
  • TABLE 49: GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 50: NORTH AMERICA :CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 51: NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 52: NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 53: NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 54: NORTH AMERICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 55: NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 56: NORTH AMERICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 57: NORTH AMERICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 58: NORTH AMERICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 59: NORTH AMERICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 60: U.S.: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 61: U.S.: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 62: U.S.: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 63: U.S.: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 64: U.S.: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 65: U.S.: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 66: U.S.: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 67: U.S.: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 68: U.S.: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 69: CANADA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 70: CANADA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 71: CANADA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 72: CANADA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 73: CANADA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 74: CANADA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 75: CANADA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 76: CANADA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 77: CANADA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 78: EUROPE :CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 79: EUROPE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 80: EUROPE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 81: EUROPE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 82: EUROPE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 83: EUROPE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 84: EUROPE: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 85: EUROPE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 86: EUROPE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 87: EUROPE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 88: GERMANY: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 89: GERMANY: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 90: GERMANY: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 91: GERMANY: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 92: GERMANY: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 93: GERMANY: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 94: GERMANY: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 95: GERMANY: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 96: GERMANY: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 97: U.K.: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 98: U.K.: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 99: U.K.: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 100: U.K.: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 101: U.K.: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 102: U.K.: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 103: U.K.: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 104: U.K.: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 105: U.K.: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 106: FRANCE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 107: FRANCE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 108: FRANCE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 109: FRANCE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 110: FRANCE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 111: FRANCE: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 112: FRANCE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 113: FRANCE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 114: FRANCE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 115: ITALY: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 116: ITALY: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 117: ITALY: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 118: ITALY: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 119: ITALY: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 120: ITALY: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 121: ITALY: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 122: ITALY: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 123: ITALY: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 124: SPAIN: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 125: SPAIN: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 126: SPAIN: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 127: SPAIN: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 128: SPAIN: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 129: SPAIN: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 130: SPAIN: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 131: SPAIN: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 132: SPAIN: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 133: ROE: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 134: ROE: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 135: ROE: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 136: ROE: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 137: ROE: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 138: ROE: IMAGING TECHNOLOGIES MARKET SIZE, 2013-2020 (USD MILLION)
  • TABLE 139: ROE: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 140: ROE: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 141: ROE: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 142: ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 143: ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 144: ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 145: ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 146: ASIA-PACIFIC: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 147: ASIA-PACIFIC: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 148: ASIA-PACIFIC: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 149: ASIA-PACIFIC: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 150: ASIA-PACIFIC: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 151: ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 152: JAPAN: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 153: JAPAN: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 154: JAPAN: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 155: JAPAN: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 156: JAPAN: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 157: JAPAN: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 158: JAPAN: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 159: JAPAN: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 160: JAPAN: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 161: CHINA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 162: CHINA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 163: CHINA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 164: CHINA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 165: CHINA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 166: CHINA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 167: CHINA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 168: CHINA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 169: CHINA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 170: INDIA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 171: INDIA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 172: INDIA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 173: INDIA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 174: INDIA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 175: INDIA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 176: INDIA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 177: INDIA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 178: INDIA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 179: REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 180: REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 181: REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 182: REST OF APAC: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 183: REST OF APAC: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 184: REST OF APAC: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 185: REST OF APAC: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 186: REST OF APAC: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 187: REST OF APAC: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 188: ROW: CANCER BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 189: ROW: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 190: ROW: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 191: ROW: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 192: ROW: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 193: ROW: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 194: ROW: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 195: ROW: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 196: ROW: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 197: ROW: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 198: LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 199: LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 200: LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 201: LATIN AMERICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 202: LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 203: LATIN AMERICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 204: LATIN AMERICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 205: LATIN AMERICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 206: LATIN AMERICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 207: MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2013-2020 (USD MILLION)
  • TABLE 208: MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 209: MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY PROFILING TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 210: MIDDLE EAST AND AFRICA: OMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 211: MIDDLE EAST AND AFRICA: GENOMICS TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 212: MIDDLE EAST AND AFRICA: IMAGING TECHNOLOGIES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 213: MIDDLE EAST AND AFRICA: IMMUNOASSAYS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 214: MIDDLE EAST AND AFRICA: CYTOGENETICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 215: MIDDLE EAST AND AFRICA: CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 216: GROWTH STRATEGY MATRIX, 2011-2015
  • TABLE 217: NEW PRODUCT LAUNCHES, 2012-2015
  • TABLE 218: AGREEMENTS, 2012-2015
  • TABLE 219: ACQUISITIONS, 2012-2015
  • TABLE 220: COLLABORATIONS
  • TABLE 221: OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
  • FIGURE 2: CANCER BIOMARKERS MARKET, BY CANCER TYPE
  • FIGURE 3: CANCER BIOMARKERS MARKET, BY TYPE
  • FIGURE 4: CANCER BIOMARKERS MARKET, BY APPLICATION
  • FIGURE 5: RESEARCH DESIGN
  • FIGURE 6: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7: BOTTOM-UP APPROACH
  • FIGURE 8: TOP-DOWN APPROACH
  • FIGURE 9: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10: GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 11: GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 12: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015 VS. 2020 (USD MILLION)
  • FIGURE 13: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 14: GEOGRAPHIC ANALYSIS: GLOBAL CANCER BIOMARKERS MARKET
  • FIGURE 15: RISING INCIDENCES OF CANCER TO DRIVE MARKET GROWTH
  • FIGURE 16: OMICS TECHNOLOGIES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CANCER BIOMARKERS MARKET
  • FIGURE 17: THE CHINA IS GROWING AT THE FASTEST GEOGRAPHIC REGION IN CANCER BIOMARKERS MARKET IN 2014
  • FIGURE 18: NORTH AMERICA TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET DURING THE FORECAST PERIOD
  • FIGURE 19: CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 20: CANCER BIOMARKERS MARKET, BY TYPE
  • FIGURE 21: CANCER BIOMARKERS MARKET, BY CANCER TYPE
  • FIGURE 22: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES
  • FIGURE 23: CANCER BIOMARKERS MARKET, BY APPLICATION
  • FIGURE 24: CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITITES, AND CHALLENGES
  • FIGURE 25: GLOBAL CANCER INCIDENCE, 2008-2025
  • FIGURE 26: INCREASING USE OF BIOMARKERS FOR THE DEVELOPMENT OF PERSONALIZED MEDICINE IS THE KEY TREND IN THE CANCER BIOMARKERS INDUSTRY
  • FIGURE 27: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 28: GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 29: GENETIC BIOMARKERS ARE EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD
  • FIGURE 30: OMICS TECHNOLOGIES WILL CONTINUE TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET IN 2020
  • FIGURE 31: GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2015 VS. 2020
  • FIGURE 32: CANCER BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT (2015-2020)
  • FIGURE 33: CHINA TO HOLD THE HIGHEST GROWTH POTENTIAL FOR ALMOST ALL SEGMENTS IN THE GLOBAL CANCER BIOMARKERS MARKET
  • FIGURE 34: NORTH AMERICA MARKET SNAPSHOT:
  • FIGURE 35: GERMANY WAS THE LARGEST MARKET FOR CANCER BIOMARKERS IN EUROPE IN 2014
  • FIGURE 36: ASIA-PACIFIC CANCER BIOMARKERS MARKET SNAPSHOT: CHINA AND INDIA ARE THE MOST LUCRATIVE MARKETS FOR CANCER BIOMARKERS
  • FIGURE 37: NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY ADOPTED BETWEEN 2012 AND 2015
  • FIGURE 38: GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 39: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY
  • FIGURE 40: GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET
  • FIGURE 41: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 42: AFFYMETRIX, INC.: COMPANY SNAPSHOT
  • FIGURE 43: ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 44: QIAGEN N.V.: COMPANY SNAPSHOT
  • FIGURE 45: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 46: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 47: QUEST DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 48: MERCK & CO, INC.: COMPANY SNAPSHOT
  • FIGURE 49: HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 50: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
Back to Top